HILE: The transaction price for the major asset purchase has been adjusted to 536 million yuanZhitong·Sep 15, 2025 at 04:13 AM603718+4.00%
HILE: The registration application for Class III medical devices of the holding subsidiary has been acceptedZhitong·Sep 10, 2025 at 02:45 AM603718+4.00%
HILE: Bone repair material registration application acceptedZhitong·Sep 1, 2025 at 04:03 AM603718+4.00%
HILE released its semi-annual performance, with a net profit attributable to the parent company of 18.23 million yuan, a year-on-year increase of 20.56%Zhitong·Aug 27, 2025 at 05:21 AM603718+4.00%
The animal vaccine sector continues to rise, with Shen Lian Biomedical up over 10%Zhitong·Jul 31, 2025 at 08:38 PM002688+1.00%688098+4.47%
HILE: Director and General Manager Han Benyi has not reduced his shareholdingZhitong·Jun 13, 2025 at 04:26 AM603718+4.00%
HILE's shareholder Zhang Le reduced his stake in the company by 0.61%Zhitong·May 8, 2025 at 02:38 AM603718+4.00%
HILE's shareholder Zhang Le completed a 2% share reductionZhitong·May 5, 2025 at 03:57 AM603718+4.00%
HILE released its first-quarter performance, with a net profit attributable to the parent company of 10.9017 million yuan, turning a profit from a lossZhitong·Apr 21, 2025 at 03:05 AM603718+4.00%
HILE released its 2024 annual performance, with a net profit attributable to the parent company of 171 million yuan, a year-on-year increase of 172.28%Zhitong·Apr 21, 2025 at 03:03 AM603718+4.00%
HILE's shareholder Zhang Le reduced his holdings by 1.26%Zhitong·Apr 16, 2025 at 04:02 AM603718+4.00%
The animal health sector is performing strongly against the trend, Jinhe Biotechnology has hit the limit up for 3 consecutive days in 6 daysZhitong·Apr 2, 2025 at 08:38 PM002688+1.00%600789+0.27%
HILE shareholder Zhang Le plans to reduce his holdings by no more than 2%Zhitong·Mar 23, 2025 at 10:46 AM603718+4.00%
HILE's director and general manager Han Benyi plans to reduce his holdings by no more than 750,000 sharesZhitong·Feb 19, 2025 at 03:34 AM603718+4.00%
